Imperva Inc (IMPV) Receives $57.06 Average Price Target from Analysts

Share on StockTwits

Shares of Imperva Inc (NASDAQ:IMPV) have been given an average recommendation of “Hold” by the seventeen brokerages that are covering the company, Marketbeat.com reports. Ten equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $57.06.

IMPV has been the topic of several analyst reports. Oppenheimer lowered Imperva from an “outperform” rating to a “market perform” rating and set a $70.00 target price on the stock. in a report on Friday, July 27th. JPMorgan Chase & Co. upped their target price on Imperva from $45.00 to $48.00 and gave the stock an “underweight” rating in a report on Friday, July 27th. BidaskClub lowered Imperva from a “strong-buy” rating to a “buy” rating in a report on Wednesday, August 1st. DA Davidson lowered Imperva from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $56.00 to $46.00 in a report on Friday, July 27th. Finally, Royal Bank of Canada lowered Imperva from an “outperform” rating to a “sector perform” rating and set a $56.00 target price on the stock. in a report on Tuesday.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. increased its position in Imperva by 4.0% during the second quarter. BlackRock Inc. now owns 2,362,641 shares of the software maker’s stock worth $113,997,000 after buying an additional 91,444 shares during the last quarter. RGM Capital LLC grew its position in shares of Imperva by 0.8% in the second quarter. RGM Capital LLC now owns 1,777,212 shares of the software maker’s stock valued at $85,750,000 after purchasing an additional 14,045 shares during the last quarter. Rothschild Asset Management Inc. grew its position in shares of Imperva by 18.4% in the second quarter. Rothschild Asset Management Inc. now owns 594,441 shares of the software maker’s stock valued at $28,682,000 after purchasing an additional 92,349 shares during the last quarter. Bank of America Corp DE grew its position in shares of Imperva by 1.2% in the second quarter. Bank of America Corp DE now owns 528,022 shares of the software maker’s stock valued at $25,478,000 after purchasing an additional 6,443 shares during the last quarter. Finally, Legal & General Group Plc grew its position in shares of Imperva by 27.9% in the second quarter. Legal & General Group Plc now owns 519,725 shares of the software maker’s stock valued at $25,077,000 after purchasing an additional 113,280 shares during the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

IMPV opened at $55.65 on Friday. Imperva has a 52-week low of $37.17 and a 52-week high of $57.65. The stock has a market cap of $1.93 billion, a P/E ratio of -198.75 and a beta of 1.35.

Imperva (NASDAQ:IMPV) last released its earnings results on Wednesday, October 31st. The software maker reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.25. Imperva had a negative return on equity of 5.68% and a negative net margin of 8.00%. The business had revenue of $91.63 million for the quarter, compared to analyst estimates of $89.24 million. On average, analysts expect that Imperva will post -1.06 EPS for the current fiscal year.

About Imperva

Imperva, Inc engages in the development, market, sale, and support of cyber security solutions that protect business critical data and applications in the cloud or on premises worldwide. The company's SecureSphere product line provides database, file, and Web application security in various data centers, including on-premises data centers, as well as in private, public, and hybrid cloud computing environments.

Featured Article: Yield Curve

Analyst Recommendations for Imperva (NASDAQ:IMPV)

Receive News & Ratings for Imperva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply